Cargando…

Immune monitoring technology primer

BACKGROUND: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. FINDINGS: The p...

Descripción completa

Detalles Bibliográficos
Autor principal: Dobbin, Kevin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615874/
https://www.ncbi.nlm.nih.gov/pubmed/26500774
http://dx.doi.org/10.1186/s40425-015-0086-9
_version_ 1782396525617348608
author Dobbin, Kevin K.
author_facet Dobbin, Kevin K.
author_sort Dobbin, Kevin K.
collection PubMed
description BACKGROUND: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. FINDINGS: The process of clinically validating a predictive biomarker is reviewed. Validation of a predictive biomarker requires quantifying the strength of a statistical interaction between marker and a treatment. Different study designs are considered. CONCLUSIONS: Clinical validation of immunology biomarkers can be demanding both in terms of time and resources, and careful planning and study design are critical.
format Online
Article
Text
id pubmed-4615874
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46158742015-10-23 Immune monitoring technology primer Dobbin, Kevin K. J Immunother Cancer Short Report BACKGROUND: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. FINDINGS: The process of clinically validating a predictive biomarker is reviewed. Validation of a predictive biomarker requires quantifying the strength of a statistical interaction between marker and a treatment. Different study designs are considered. CONCLUSIONS: Clinical validation of immunology biomarkers can be demanding both in terms of time and resources, and careful planning and study design are critical. BioMed Central 2015-10-20 /pmc/articles/PMC4615874/ /pubmed/26500774 http://dx.doi.org/10.1186/s40425-015-0086-9 Text en © Dobbin. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Dobbin, Kevin K.
Immune monitoring technology primer
title Immune monitoring technology primer
title_full Immune monitoring technology primer
title_fullStr Immune monitoring technology primer
title_full_unstemmed Immune monitoring technology primer
title_short Immune monitoring technology primer
title_sort immune monitoring technology primer
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615874/
https://www.ncbi.nlm.nih.gov/pubmed/26500774
http://dx.doi.org/10.1186/s40425-015-0086-9
work_keys_str_mv AT dobbinkevink immunemonitoringtechnologyprimer